BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Partnership

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $37 million target selection payment for two additional programs selected - - Regeneron secures option

Related news

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIXNurix Therapeutics2026-06-08 05:00 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-07-27 12:00 EST

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

IDYAIDEAYA Biosciences2026-06-03 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-08-03 12:00 EST

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CTMXCytomX Therapeutics, Inc.2026-07-27 12:00 EST

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CTMXCytomX Therapeutics, Inc.2026-06-03 12:00 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Stock data

Close
3.37 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States